Sol-Gel Technologies PE Ratio 2016-2023 | SLGL
Current and historical p/e ratio for Sol-Gel Technologies (SLGL) from 2016 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Sol-Gel Technologies PE ratio as of April 24, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Sol-Gel Technologies PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-04-24 |
0.92 |
|
0.00 |
| 2023-12-31 |
1.11 |
$-1.01 |
0.00 |
| 2023-09-30 |
1.63 |
$-1.09 |
0.00 |
| 2023-06-30 |
2.99 |
$-1.03 |
0.00 |
| 2023-03-31 |
3.88 |
$-0.82 |
0.00 |
| 2022-12-31 |
4.56 |
$-0.65 |
0.00 |
| 2022-09-30 |
5.02 |
$0.21 |
23.90 |
| 2022-06-30 |
4.10 |
$0.41 |
10.00 |
| 2022-03-31 |
7.38 |
$0.07 |
105.43 |
| 2021-12-31 |
7.40 |
$0.13 |
56.92 |
| 2021-09-30 |
10.00 |
$-0.84 |
0.00 |
| 2021-06-30 |
12.38 |
$-1.26 |
0.00 |
| 2021-03-31 |
12.38 |
$-1.22 |
0.00 |
| 2020-12-31 |
9.79 |
$-1.37 |
0.00 |
| 2020-09-30 |
7.24 |
$-1.33 |
0.00 |
| 2020-06-30 |
8.95 |
$-1.33 |
0.00 |
| 2020-03-31 |
7.06 |
$-1.28 |
0.00 |
| 2019-12-31 |
17.15 |
$-1.25 |
0.00 |
| 2019-09-30 |
8.99 |
$-2.33 |
0.00 |
| 2019-06-30 |
9.11 |
$-2.36 |
0.00 |
| 2019-03-31 |
6.77 |
$-2.46 |
0.00 |
| 2018-12-31 |
6.02 |
$-2.55 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.026B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
